UW Labs Work to Prevent and Treat Diabetes
Researchers at the University of Wisconsin are studying insulin-producing beta cells to prevent and treat both Type 1 and Type 2 diabetes.
Updated on Nov. 18, 2026 in Diseases

Live Poll
Have you had a checkup in the past year to screen for diabetes risk?
University of Wisconsin researchers are studying the insulin-producing beta cells of the pancreas to prevent and treat diabetes during National Diabetes Month in November. The Davis Lab is running a clinical trial that transplants stem cell-derived beta cells into patients with Type 1 diabetes.
Why it matters
Diabetes causes high blood sugar by disrupting insulin, a hormone that regulates blood glucose, so restoring or protecting beta cells targets the underlying cause rather than only managing symptoms. Work of this kind could matter to Wisconsin residents as rates of Type 2 diabetes rise among younger adults and college students.
The evidence consists of ongoing laboratory work and a clinical trial rather than published outcome data, and the source does not give enrollment figures or results. Reported trends point to rising Type 2 diabetes among younger adults and college students, but no quantified rate was provided.
The players
University of Wisconsin
A public research university in Madison, Wisconsin, home to the Davis and Engin laboratories conducting this diabetes research.
Dawn Davis Laboratory for Intra-Islet Signaling in Diabetes
A University of Wisconsin research lab focused on promoting the health of beta cells and running a clinical trial of stem cell-derived beta cell transplants.
John Odorcio
A University of Wisconsin transplant surgeon collaborating with the Davis Lab on its clinical trial for Type 1 diabetes patients.
The details
Stressed beta cells send signals that communicate with immune cells and change their surface structure, which marks them for attack, according to the Engin Lab's study of healthy versus stressed cells. The Davis Lab, working with UW transplant surgeon John Odorcio, is transplanting stem cell-derived beta cells into Type 1 diabetic patients while also working to slow progression and restore function in patients who have lost beta cell activity.
Timeline
November is National Diabetes Month, the period in which the research is being highlighted.
Big Picture
The Dawn Davis Laboratory for Intra-Islet Signaling in Diabetes is pursuing a dual approach of preventing progression in early disease and restoring beta cell function in patients who have lost it. This clinical trial of stem cell-derived beta cells extends that research program from the laboratory toward treatment of Type 1 diabetes patients.
For people living with Type 1 diabetes, the Davis Lab trial represents a possible future option built on transplanted beta cells rather than daily insulin alone, though participation and availability are not described in the source. Adults and college-age readers concerned about Type 2 diabetes may find the reported rise among younger people a reason to track blood sugar and weight-related risk factors with a clinician.
The takeaway
Insulin resistance tends to increase with age, weight gain, and obesity, so maintaining a healthy weight and discussing blood sugar screening with a doctor are practical steps readers can take now. Protecting the body's insulin-producing cells early is a central goal of this research.
Further reading
Explore more on Diabetes coverage from across Wisconsin.
Source note: This article includes information reported by The Badger Herald.
Live Poll
Have you had a checkup in the past year to screen for diabetes risk?






